2024
Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments
Lambert C, Hussain T, Peters J, Longbrake E. Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments. Multiple Sclerosis And Related Disorders 2024, 94: 106236. PMID: 39755026, PMCID: PMC11869388, DOI: 10.1016/j.msard.2024.106236.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexAnti-CD20 medicationsDisease-modifying treatmentsDMT useS1P modulatorsImmunomodulatory treatmentImmune cellsSevere infectionsMultiple sclerosisLong-term immunomodulatory treatmentReal-life practice patternsTreatment durationInfection rateSelection of patientsClinical selection of patientsDeplete immune cellsObservational cohort studyBody mass indexSevere infection rateAnalyzed medical recordsIncreased infection riskInfection riskDisease modifying therapiesMultiple sclerosis patientsImmune subsets
2021
Influence of immunomodulatory drugs on the gut microbiota
Cohen I, Ruff WE, Longbrake EE. Influence of immunomodulatory drugs on the gut microbiota. Translational Research 2021, 233: 144-161. PMID: 33515779, PMCID: PMC8184576, DOI: 10.1016/j.trsl.2021.01.009.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityCell ProliferationCytokinesFemaleGastrointestinal MicrobiomeHost Microbial InteractionsHumansImmune Checkpoint InhibitorsImmunity, InnateImmunity, MucosalImmunologic FactorsImmunomodulationLymphocytesMaleModels, ImmunologicalSex FactorsTranslational Research, BiomedicalConceptsImmune checkpoint inhibitorsGut microbiotaCheckpoint inhibitorsAutoimmune diseasesMainstay of treatmentType of immunotherapyInflammatory cytokine inhibitorComprehensive literature searchMechanism of actionImmunomodulatory medicationsDrug-induced shiftImmunomodulatory drugsCytokine inhibitorsImmunotherapy effectImmune cellsClinical significanceImmune responseMost immunotherapiesCommensal microbesDrug efficacyImmunotherapyLiterature searchAntiproliferative drugsMedicationsMicrobiota
2015
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
Longbrake E, Ramsbottom M, Cantoni C, Ghezzi L, Cross A, Piccio L. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Multiple Sclerosis Journal 2015, 22: 1061-1070. PMID: 26459150, PMCID: PMC4829494, DOI: 10.1177/1352458515608961.Peer-Reviewed Original ResearchConceptsDMF-treated patientsMemory T cellsMultiple sclerosis patientsT cellsMS patientsDendritic cellsSclerosis patientsEffector memory T cellsUntreated MS patientsMyeloid dendritic cellsAbsolute lymphocyte countPlasmacytoid dendritic cellsNatural killer cellsNaïve T cellsMechanism of actionLymphocyte countLymphopenic patientsRegulatory cellsKiller cellsPeripheral bloodImmune cellsHealthy controlsPatientsB cellsFlow cytometry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply